JOP20210193A1 - مثبطات pcsk9 وطرق استخدامها - Google Patents

مثبطات pcsk9 وطرق استخدامها

Info

Publication number
JOP20210193A1
JOP20210193A1 JOP/2021/0193A JOP20210193A JOP20210193A1 JO P20210193 A1 JOP20210193 A1 JO P20210193A1 JO P20210193 A JOP20210193 A JO P20210193A JO P20210193 A1 JOP20210193 A1 JO P20210193A1
Authority
JO
Jordan
Prior art keywords
methods
pcsk9 inhibitors
treating
novel
relates
Prior art date
Application number
JOP/2021/0193A
Other languages
English (en)
Inventor
Mark Chambers
Jason Tierney
Karamjit Jandu
Erica Goldsmith
Michael H Serrano-Wu
David Clark
Paul Hinchliffe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20210193A1 publication Critical patent/JOP20210193A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع بمركبات أريل غير متجانسة جديدة ومستحضرات صيدلانية منها. يتعلق الاختراع أيضاً بطرق لعلاج أو الوقاية من أمراض قلبية وعائية، وطرق لعلاج الإنتان أو الصدمة الإنتانية، باستخدام المركبات الحلقية غير المتجانسة الجديدة التي تم الكشف عنها في هذه الوثيقة.
JOP/2021/0193A 2019-01-18 2020-01-16 مثبطات pcsk9 وطرق استخدامها JOP20210193A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794234P 2019-01-18 2019-01-18
PCT/US2020/013881 WO2020150473A2 (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
JOP20210193A1 true JOP20210193A1 (ar) 2023-01-30

Family

ID=71613436

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0193A JOP20210193A1 (ar) 2019-01-18 2020-01-16 مثبطات pcsk9 وطرق استخدامها

Country Status (22)

Country Link
US (2) US11248001B2 (ar)
EP (1) EP3911648B1 (ar)
JP (2) JP7128969B2 (ar)
KR (1) KR20210116548A (ar)
CN (1) CN113574055B (ar)
AU (1) AU2020209215B2 (ar)
BR (1) BR112021013807A2 (ar)
CA (1) CA3125765A1 (ar)
CL (1) CL2021001859A1 (ar)
CO (1) CO2021010312A2 (ar)
CR (1) CR20210441A (ar)
DO (1) DOP2021000150A (ar)
EA (1) EA202191892A1 (ar)
EC (1) ECSP21060240A (ar)
IL (1) IL284640A (ar)
JO (1) JOP20210193A1 (ar)
MA (1) MA54261A (ar)
MX (1) MX2021008533A (ar)
PE (1) PE20220138A1 (ar)
SG (1) SG11202107614PA (ar)
TW (1) TWI852981B (ar)
WO (1) WO2020150473A2 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202039426A (zh) 2018-11-30 2020-11-01 美商彗星製藥公司 泛硫醇（Ｐａｎｔｅｔｈｅｉｎｅ）衍生物及其用途
EA202191890A1 (ru) * 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114890988A (zh) * 2022-04-28 2022-08-12 浙江工业大学 一种沙利度胺的化学合成方法
WO2024013209A1 (en) * 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2024078620A1 (zh) * 2022-10-14 2024-04-18 上海翰森生物医药科技有限公司 含氮杂环类衍生物抑制剂、其制备方法和应用
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US267A (en) 1837-07-11 Mcode of hanging ob suspending a band-wheel in those hobse-powebs in
US2937169A (en) 1960-05-17 Toiutf alrtqn of h
US3262852A (en) 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
US30577A (en) 1860-11-06 Truss-bridge
US2809194A (en) 1957-10-08 Thiadiazine type natriuretic agents
US2882271A (en) 1959-04-14 Xcixcxh
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US238A (en) 1837-06-15 Capstan
US3962A (en) 1845-03-21 Fowler m
SE168308C1 (ar)
US3009911A (en) 1961-11-21 Derivatives of j
US3254076A (en) 1966-05-31 Sulfamyl hydro
US2661372A (en) 1953-12-01 Pharmacologically valuable stereo
US3108097A (en) 1963-10-22 Ehnojs
US2976289A (en) 1961-03-21 X-tetrahydro -
US115905A (en) 1871-06-13 Improvement in trunks
US3935A (en) 1845-02-28 Improvement in machines for cutting sausage-meat
US3562A (en) 1844-04-25 Improvement in seed-planters
US3164588A (en) 1965-01-05 Hjnsoj
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2357985A (en) 1940-07-30 1944-09-12 Research Corp Synthesis of hexoestrol
DE905738C (de) 1943-06-11 1954-11-02 Diwag Chemische Fabriken Ag Verfahren zur Herstellung basischer Thymoldimethylaminoaethylaether
US2500444A (en) 1944-10-10 1950-03-14 Polaroid Corp Uramidohomomeroquinene
AT168063B (de) 1948-11-23 1951-04-10 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen asymmetrischen Substitutionsprodukten des 2,4-Diamino-1,3,5-Triazins
DE860217C (de) 1950-10-28 1952-12-18 Albert Ag Chem Werke Verfahren zur Herstellung von 1-Hexyl-3, 7-dimethylxanthin
GB740932A (en) 1952-08-01 1955-11-23 Rhone Poulenc Sa Improvements in or relating to phenthiazine derivatives
US2661373A (en) 1953-03-02 1953-12-01 Kulz Ida Certain amino alcohols and ketones
US2816118A (en) 1953-11-12 1957-12-10 S B Penick & Company Inc Isolation of crystalline components from visnagan
FR1103113A (fr) 1954-04-15 1955-10-31 Triméthylol-alcanes et leur procédé de préparation
GB769757A (en) 1954-05-13 1957-03-13 American Cyanamid Co Improvements in or relating to the manufacture of sulfonamides
US2769015A (en) 1954-10-06 1956-10-30 Lab Laroche Navarron Process of preparing 3-methyl-chromone
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
GB807826A (en) 1955-03-14 1959-01-21 Thomae Gmbh Dr K Derivatives of pyrimido[5,4-d] pyrimidine and production thereof
FR1165845A (fr) 1955-05-28 1958-10-29 Philips Nv Amines secondaires portant des substituants et leur préparation
GB803372A (en) 1955-11-02 1958-10-22 Recordati Lab Farmacologico S Hydroxychromone derivatives and methods of preparing the same
US3012042A (en) 1956-12-21 1961-12-05 Belge Produits Chimiques Sa Benzofurans
NL224562A (ar) 1957-02-05
US2980679A (en) 1957-04-04 1961-04-18 Omikron Gagliardi Societa Di F Process for preparing heterocyclic sulfonamides
GB824547A (en) 1957-05-07 1959-12-02 Recordati Lab Farmacologico S Process for preparing flavone-7-ethyl oxyacetate
US3055904A (en) 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
US2965656A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino-2, 4-benzene-disulfonamides
US2965655A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino 2, 4-benzene-disulfonamides
US2980699A (en) 1957-12-20 1961-04-18 S B Penick And Company Dihydropyranocoumarin derivatives and process for their production
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
CH366523A (de) 1958-04-14 1963-01-15 Eprova Ag Verfahren zur Herstellung der neuen 1,3,4,6- und 1,3,4,5-Tetranicotinoyl-fructose
BE578515A (ar) 1958-05-07
GB851287A (en) 1958-07-10 1960-10-12 British Drug Houses Ltd 5-chlorotoluene-2:4-disulphonamide and alkali metal salts thereof
DE1102750B (de) 1958-07-17 1961-03-23 Wuelfing J A Fa Verfahren zur Herstellung eines Salzes von Theophyllinbasen
GB856409A (en) 1958-07-26 1960-12-14 Chime Et Atomistique Improvements in and relating to a new pyridazine derivative and its process of preparation
GB862248A (en) 1958-08-04 1961-03-08 Italseber S P A Di-isopropylammonium salts of chloroacetic and chloropropionic acids
US2970082A (en) 1958-10-07 1961-01-31 Walker Lab Inc Aluminum nicotinate compositions for hypercholesteremia
GB885078A (en) 1959-01-12 1961-12-20 Ciba Ltd 3:4-dihydro-1:2:4-benzothiadiazine-1:1-dioxides and process for their manufacture
ES255386A1 (es) 1959-02-04 1960-09-16 Ciba Geigy Procedimiento para preparar derivados del 3,4-dihidro-1,2,4-benzotiadiazina-1,1,-diëxido
US3058882A (en) 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
DE1102973B (de) 1960-03-25 1961-03-23 Bayer Ag Verfahren zur Herstellung von hoch gereinigten Kallikrein-Praeparaten
NL291944A (ar) 1960-05-04
DE1265758B (de) 1960-05-25 1968-04-11 Guidotti & C Spa Labor Verfahren zur Herstellung von o-(beta-Dialkylaminoaethoxy)-phenylketonen und deren Saeureadditionssalzen und quartaeren Salzen
US3081230A (en) 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
DE1302648B (ar) 1960-09-27
SE300218B (ar) 1960-11-08 1968-04-22 Recip Ab
NL270803A (ar) 1960-11-09
US3255241A (en) 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
US3072653A (en) 1961-03-06 1963-01-08 Warner Lamber Pharmaceutical C 5-amino derivatives of 4-thiazolidinones and process therefor
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
FR1312427A (fr) 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
GB979994A (en) 1961-07-28 1965-01-06 May & Baker Ltd Isoindolinone derivatives
NL281593A (ar) 1961-07-31
US3160641A (en) 1961-08-07 1964-12-08 Atlas Chem Ind Purification of isosorbide
NL281975A (ar) 1961-08-12
GB984810A (en) 1961-10-05 1965-03-03 Farmaceutici Italia Polypeptides
DE1236523C2 (de) 1962-02-15 1975-06-12 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim Verfahren zur herstellung von basischen phenylaethern und deren salzen
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE629910A (ar) 1962-03-22
US3188329A (en) 1962-04-10 1965-06-08 Colgate Palmolive Co Diuretic anils
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
US3338899A (en) 1962-07-09 1967-08-29 Aron Samuel 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds
US3265573A (en) 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
BE639386A (ar) 1962-10-30
NL300886A (ar) 1962-11-23
NL301580A (ar) 1962-12-11
NL142872C (ar) 1963-03-28
FR1365504A (fr) 1963-05-24 1964-07-03 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés des thiachromanes et procédé de préparation
FR2790M (fr) 1963-05-24 1964-10-16 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés des thiachromanes.
GB1069343A (en) 1963-09-10 1967-05-17 Ici Ltd Propanolamine derivatives
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
NL127996C (ar) 1963-11-19
BR6464291D0 (pt) 1963-11-26 1973-07-26 Merrell Inc Richardson Processo para preparar o novo composto quimico 1-1-di cloro-hexil-2-(2-piperidil)-etina
DE1278443C2 (de) 1963-11-30 1975-07-24 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,4-disulfonamid-1-chlorbenzolen
NL128190C (ar) 1964-02-07
FR1390056A (fr) 1964-04-21 1965-02-19 Holding Ceresia S A Procédé de préparation de nouveaux dérivés du tétrahydronaphtalène et produits conformes à ceux obtenus par le présent procédé ou procédé similaire
NL127065C (ar) 1964-04-22
NL137318C (ar) 1964-06-09
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
NL130749C (ar) 1964-09-10
GB1078852A (en) 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
NL6514807A (ar) 1964-11-18 1966-05-20
GB1084150A (ar) 1965-01-12
US3929836A (en) 1965-05-11 1975-12-30 Hoffmann La Roche 2-(2-Lower alkylamino-1-hydroxy-ethyl)-substituted benzofurans
FR1460571A (fr) 1965-06-10 1966-03-04 Innothera Lab Sa Composés thiényl acétiques et leur préparation
DE1270544B (de) 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
DE1545575C2 (de) 1965-12-16 1970-09-10 Asta-Werke Ag, Chemische Fabrik, 4812 Brackwede N, N'-Bis- eckige Klammer auf 3"(3', 4', 5'-trimethoxybenzoyloxy)-propyl eckige Klammer zu -homopiperazin
US3360518A (en) 1966-01-03 1967-12-26 Wallace & Tiernan Inc Tetrahydro-halo-sulfamyl quinazolinones
CH472404A (de) 1966-03-04 1969-05-15 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
CH469002A (de) 1966-06-21 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
FR5733M (ar) 1966-09-27 1968-01-22
FR6087M (ar) 1967-01-10 1968-06-04
US3940489A (en) 1967-02-06 1976-02-24 Boehringer Ingelheim Gmbh Therapeutic compositions and method
US3961071A (en) 1967-02-06 1976-06-01 Boehringer Ingelheim Gmbh Therapeutic compositions and method
GB1160925A (en) 1967-02-08 1969-08-06 Menarini Sas 2-Substituted Benzofuran Derivatives
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3563997A (en) 1967-12-04 1971-02-16 Yoshitomi Pharmaceutical Certain thieno(2,3-c)pyridines
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
FR2003097A1 (en) 1968-03-02 1969-11-07 Takeda Chemical Industries Ltd Cpds. of general formula (I) A=CH or N Spasmolytics and peripheral vasodilators. Dose: 100-200 mg/d. (p.o). Z and X are OH or reactive
GB1203691A (en) 1968-03-06 1970-09-03 Science Union & Cie New disubstituted n-amino indoline derivatives and process for preparing them
GB1218591A (en) 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
US4045482A (en) 1968-11-12 1977-08-30 Yamanouchi Pharmaceutical Co. Ltd. 4-(3-Isopropylamino-2-hydroxypropoxy indene
DE1815922C3 (de) 1968-12-20 1979-04-26 Boehringer Mannheim Gmbh, 6800 Mannheim 5-Phenyltetrazol-Derivate
FR8120M (ar) 1968-12-26 1970-08-03
GB1285038A (en) 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3836671A (en) 1969-02-21 1974-09-17 Ici Ltd Alkanolamine derivatives for producing beta-adrenergic blockade
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3663570A (en) 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
GB1262785A (en) 1969-04-29 1972-02-09 Orsymonde Improvements in or relating to phloroglucinol derivatives
CA956632A (en) 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
US4012444A (en) 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
US3634583A (en) 1969-07-24 1972-01-11 Leo Pharm Prod Ltd Pharmaceutical composition for the treatment of oedematous conditions and hypertension
BE757001A (fr) 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation
US4018824A (en) 1969-11-28 1977-04-19 Teikoku Hormone Mfg. Co., Ltd. 1-Aryloxy-3-aminopropane derivatives
US4038313A (en) 1970-01-08 1977-07-26 Ciba-Geigy Corporation Cycloalkylureido phenoxy propanolamines
US3935259A (en) 1970-01-08 1976-01-27 Ciba-Geigy Corporation New amines and processes for their manufacture
SE354851B (ar) 1970-02-18 1973-03-26 Haessle Ab
US3770724A (en) 1970-03-31 1973-11-06 Roussel Uclaf Process for preparing pentacyclic alkaloids
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3663597A (en) 1970-05-05 1972-05-16 American Home Prod Process for the purification of cyclandelate
FR2092133B1 (ar) 1970-05-06 1974-03-22 Orsymonde
US3669968A (en) 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US4059622A (en) 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
FR2092895B1 (ar) 1970-06-29 1973-07-13 Lafon Victor
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
CA989411A (en) 1971-05-13 1976-05-18 Kakenyaku Kako Co. Benzofuran derivatives and preparation thereof
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
JPS5229318B2 (ar) 1972-03-30 1977-08-01
US3910924A (en) 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
ZA732937B (en) 1972-05-05 1974-03-27 Maggioni & C Spa Non mercurial diuretics
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US3985758A (en) 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
GB1390748A (en) 1973-04-09 1975-04-16 Continental Pharma Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
DE2319278C2 (de) 1973-04-17 1986-02-20 Bayer Ag, 5090 Leverkusen Pharmazeutisches Mittel
US3857981A (en) 1973-06-20 1974-12-31 Armour & Co Preserving red color in red meats
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4146643A (en) 1973-12-18 1979-03-27 Sandoz Ltd. Increasing vigilance or treating cerebral insufficiency with substituted vincamines
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
GB1501632A (en) 1974-06-28 1978-02-22 Cm Ind Aromatic ketones having cardiovascular activity
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2521113A1 (de) 1974-05-15 1976-03-18 Maggioni & C Spa Cycloaliphatische derivate von 3.3-diphenylpropylamin
JPS5612114B2 (ar) 1974-06-07 1981-03-18
US4338322A (en) 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4129565A (en) 1975-07-11 1978-12-12 Nisshin Flour Milling Co., Ltd. Isocarbostyril derivatives
US4340541A (en) 1975-08-15 1982-07-20 Sandoz Ltd. 4-(2-Benzoyloxy-3-tert.-butylaminopropoxy-2-methyl indole
US4035750A (en) 1975-10-14 1977-07-12 Eastman Kodak Company Electrophotographic apparatus having improved photoconductor regenerative structure and procedure
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4154839A (en) 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
GB1544872A (en) 1976-06-25 1979-04-25 Sterling Drug Inc 4-hydroxyphenylalkanolamine derivatives and preparation thereof
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1088554B (it) 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
JPS5953920B2 (ja) 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
JPS55301A (en) 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
SE429652B (sv) 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
JPS559058A (en) 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
SE8004087L (sv) 1980-06-02 1981-12-03 Haessle Ab Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-er med betareceptorblockerande egenskaper, samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma, och metod att behandla akut ...
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ES8207217A1 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
US4470972A (en) 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
FR2496699B1 (fr) 1980-12-22 1985-06-21 Siderurgie Fse Inst Rech Lance de soufflage de gaz oxydant, notamment d'oxygene, pour le traitement des metaux en fusion
DE3166093D1 (en) 1981-01-05 1984-10-18 Takeda Chemical Industries Ltd N-substituted pseudo-aminosugars, their production and use
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
JPS57209270A (en) 1981-06-19 1982-12-22 Chugai Pharmaceut Co Ltd Proline derivative
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
CA1341296C (en) 1981-12-29 2001-09-25 Hansjorg Urbach 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use
US4555502A (en) 1982-09-30 1985-11-26 Merck & Co., Inc. Aminoacyl-containing dipeptide derivatives useful as antihypertensives
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
EP0094159B1 (en) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
JPS6058233B2 (ja) 1982-05-24 1985-12-19 田辺製薬株式会社 ２−オキソイミダゾリジン誘導体及びその製法
US4452790A (en) 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4463176A (en) 1982-09-13 1984-07-31 Mead Johnson & Company Process for resolution of optical isomers
AU557175B2 (en) 1982-10-15 1986-12-11 Kyowa Hakko Kogyo Co. Ltd. 2,6-dimethyl-4-(3-nitro phenyl)-1,4-dihydro pyridine-3,5- dicarboxylic acid esters
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DK520784A (da) 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
JPS60222472A (ja) 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
SU1435151A3 (ru) 1984-04-10 1988-10-30 Санкио Компани Лимитед (Фирма) Способ получени производных пергидротиазепина или их кислотно-аддитивных фармацевтически приемлемых солей
US4672068A (en) 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4634765A (en) 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
AU587057B2 (en) 1985-07-29 1989-08-03 Santen Pharmaceutical Co. Ltd. 1,4-dihydro-3-oxo-2-(substituted phenyl)-benzothiazine derivatives
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DK171349B1 (da) 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
DE3768658D1 (de) 1987-08-03 1991-04-18 Delagrange Lab 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
SG139553A1 (en) 1988-10-13 2008-02-29 Novartis Ag 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
DE3836675A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
EP0395768A4 (en) 1988-11-11 1991-05-15 Banyu Pharmaceutical Co., Ltd. Substituted allylamine derivatives, process for their preparation and their use
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
ES2084801T3 (es) 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5102915A (en) 1990-03-22 1992-04-07 Merrell Dow Pharmaceuticals Inc. Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5051534A (en) 1990-03-22 1991-09-24 Merrell Dow Pharmaceuticals Inc. Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5011859A (en) 1990-03-30 1991-04-30 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5064864A (en) 1990-03-30 1991-11-12 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
NZ239022A (en) 1990-07-25 1993-11-25 Merrell Dow Pharma Piperidyl ethers and thioethers; preparatory processes and pharmaceutical compositions
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5084461A (en) 1991-03-27 1992-01-28 Merrell Dow Pharmaceuticals Inc. Azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU3095792A (en) 1991-12-16 1993-07-19 Yamanouchi Pharmaceutical Co., Ltd. Novel amino alcohol derivative or salt thereof
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5629295A (en) 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5350758A (en) 1992-07-08 1994-09-27 Merrell Dow Pharmaceuticals Inc. Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
EP0662962A1 (en) 1992-09-28 1995-07-19 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
FR2697250B1 (fr) 1992-10-28 1995-01-20 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
DE4309553A1 (de) 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
CA2342471C (en) 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
AP9600817A0 (en) 1995-06-06 1996-07-31 Pfizer Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
JPH105585A (ja) 1996-06-27 1998-01-13 Toagosei Co Ltd リチウムイオン吸着剤
KR100334567B1 (ko) 1996-11-27 2002-05-03 디. 제이. 우드, 스피겔 알렌 제이 아포 비-분비/엠티피 억제성 아미드
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
WO2002064549A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
WO2002064130A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
CN1215067C (zh) 2001-03-30 2005-08-17 辉瑞产品公司 哒嗪酮醛糖还原酶抑制剂
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP2008502736A (ja) * 2004-06-09 2008-01-31 アバニール・ファーマシューティカルズ 高脂血症および関連疾患の治療のための複素環式誘導体
JP2008531596A (ja) * 2005-02-25 2008-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染を治療または予防するのに有用なベンゾイソチアゾール
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
WO2011006000A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Berberine derivatives useful for modulating lipid levels and their methods of synthesis
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
JP2013509194A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ２１３およびａｘ１３２ｐｃｓｋ９アンタゴニストおよびバリアント
WO2011053759A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20130056871A (ko) 2010-04-13 2013-05-30 브리스톨-마이어스 스큅 컴퍼니 Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
KR20170078865A (ko) 2010-06-04 2017-07-07 코와 가부시키가이샤 광학 활성 디벤질아민 유도체 및 그의 제조 방법
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2012101253A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
BR112013032667A2 (pt) 2011-06-20 2017-12-12 Genentech Inc polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra
WO2013008185A1 (en) 2011-07-14 2013-01-17 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
MY170089A (en) 2011-09-16 2019-07-04 Regeneron Pharma Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
WO2013091103A1 (en) 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
JPWO2013137371A1 (ja) * 2012-03-15 2015-08-03 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20140093513A1 (en) * 2012-05-25 2014-04-03 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein conversate subtilisin/kexin type 9 (pcsk9)
TW201410706A (zh) 2012-06-15 2014-03-16 Genentech Inc 抗－ｐｃｓｋ９抗體、調配物、劑量及使用方法
WO2014005224A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014127316A2 (en) 2013-02-15 2014-08-21 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
JP2016511274A (ja) 2013-03-15 2016-04-14 アデイラタ・リミテッド・パートナーシップ Ｐｃｓｋ９の小分子モジュレータ及びその使用法
EP2970501A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
BR112015023294A2 (pt) 2013-03-15 2017-07-18 Shifa Biomedical Corp método para tratamento ou prevenção de uma doença
WO2014144080A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
KR101695582B1 (ko) 2013-04-17 2017-01-13 화이자 인코포레이티드 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
CN111920954A (zh) 2013-06-07 2020-11-13 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
EP3689913B1 (en) 2013-10-11 2022-03-23 Sanofi Biotechnology Use of a pcsk9 inhibitor to treat hyperlipidemia
JP6616298B2 (ja) 2013-11-12 2019-12-04 サノフィ・バイオテクノロジー Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
KR20220157516A (ko) 2014-03-17 2022-11-29 사노피 바이오테크놀로지 심혈관 위험을 감소시키는 방법
US20150283236A1 (en) 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
WO2015200438A1 (en) 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения

Also Published As

Publication number Publication date
JP2022116083A (ja) 2022-08-09
CA3125765A1 (en) 2020-07-23
TW202043213A (zh) 2020-12-01
EP3911648B1 (en) 2024-10-23
PE20220138A1 (es) 2022-01-27
SG11202107614PA (en) 2021-08-30
TWI852981B (zh) 2024-08-21
JP7128969B2 (ja) 2022-08-31
AU2020209215A1 (en) 2021-08-26
IL284640A (en) 2021-08-31
BR112021013807A2 (pt) 2021-11-30
US11248001B2 (en) 2022-02-15
EP3911648A2 (en) 2021-11-24
CN113574055A (zh) 2021-10-29
EP3911648A4 (en) 2022-10-26
CO2021010312A2 (es) 2021-09-20
JP2022518015A (ja) 2022-03-11
KR20210116548A (ko) 2021-09-27
AU2020209215B2 (en) 2023-02-02
EA202191892A1 (ru) 2022-02-24
CR20210441A (es) 2022-03-11
ECSP21060240A (es) 2021-09-30
CN113574055B (zh) 2024-07-23
CL2021001859A1 (es) 2022-01-14
WO2020150473A2 (en) 2020-07-23
US20200291041A1 (en) 2020-09-17
US20220220122A1 (en) 2022-07-14
WO2020150473A3 (en) 2021-02-04
MA54261A (fr) 2022-04-27
DOP2021000150A (es) 2021-08-31
MX2021008533A (es) 2021-08-19

Similar Documents

Publication Publication Date Title
JOP20210193A1 (ar) مثبطات pcsk9 وطرق استخدامها
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MY197478A (en) Compositions and methods for inhibiting arginase activity
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
EA202091709A1 (ru) Ингибиторы днк-пк
EA200970738A1 (ru) Ингибиторы активности akt
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
EA202091708A1 (ru) Ингибиторы днк-пк
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
EA201790838A1 (ru) Ингибитор киназы aurora a
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
EA202192746A1 (ru) Гетероциклические соединения и их применение
PH12018501646A1 (en) Compositions and methods for treating infections
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
MX2023000198A (es) Inhibidores de atr y usos de estos.
ZA202106519B (en) Caspase inhibitors and methods of use thereof